Zacks: Analysts Expect Adaptimmune Therapeutics plc (NASDAQ:ADAP) Will Post Earnings of -$0.28 Per Share

Brokerages expect Adaptimmune Therapeutics plc (NASDAQ:ADAPGet Rating) to announce ($0.28) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.32). Adaptimmune Therapeutics posted earnings per share of ($0.24) in the same quarter last year, which would suggest a negative year-over-year growth rate of 16.7%. The company is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year earnings of ($1.18) per share for the current year, with EPS estimates ranging from ($1.33) to ($0.99). For the next year, analysts expect that the company will post earnings of ($0.86) per share, with EPS estimates ranging from ($1.42) to ($0.55). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAPGet Rating) last released its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Adaptimmune Therapeutics had a negative return on equity of 76.84% and a negative net margin of 1,836.31%. During the same period in the prior year, the business earned ($0.24) earnings per share.

A number of analysts have recently commented on ADAP shares. Zacks Investment Research downgraded Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 15th. StockNews.com began coverage on Adaptimmune Therapeutics in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, SVB Leerink reduced their target price on Adaptimmune Therapeutics from $7.00 to $3.00 and set a “market perform” rating for the company in a report on Tuesday, March 15th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Adaptimmune Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $6.92.

Shares of NASDAQ:ADAP opened at $1.35 on Friday. The business’s 50-day moving average is $1.95 and its 200 day moving average is $3.10. The firm has a market capitalization of $211.77 million, a P/E ratio of -1.25 and a beta of 2.07. Adaptimmune Therapeutics has a 1 year low of $1.26 and a 1 year high of $6.86.

Institutional investors have recently modified their holdings of the stock. Baillie Gifford & Co. lifted its holdings in Adaptimmune Therapeutics by 11.8% during the 1st quarter. Baillie Gifford & Co. now owns 15,380,538 shares of the biotechnology company’s stock worth $31,684,000 after buying an additional 1,624,186 shares in the last quarter. Rock Springs Capital Management LP lifted its position in shares of Adaptimmune Therapeutics by 41.7% during the 3rd quarter. Rock Springs Capital Management LP now owns 2,189,788 shares of the biotechnology company’s stock worth $11,321,000 after purchasing an additional 644,788 shares during the last quarter. Long Focus Capital Management LLC purchased a new position in shares of Adaptimmune Therapeutics in the 4th quarter valued at about $8,109,000. Millennium Management LLC raised its position in shares of Adaptimmune Therapeutics by 3.7% during the 4th quarter. Millennium Management LLC now owns 1,643,478 shares of the biotechnology company’s stock worth $6,163,000 after acquiring an additional 58,629 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Adaptimmune Therapeutics during the third quarter worth approximately $8,033,000.

About Adaptimmune Therapeutics (Get Rating)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

Further Reading

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.